Abstract
The efficacy and safety of linaclotide for the treatment of constipation-predominant IBS (IBS-C) has been confirmed (up to 6 months) by two new phase III trials reported in the American Journal of Gastroenterology. The results of these trials support the recent FDA approval of linaclotide for the treatment of chronic idiopathic constipation and IBS-C.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
